Clinical DevelopmentGH001 showed impressive reduction in depression scores in the Phase 2b trial for treatment-resistant depression, with a significant number of patients achieving remission.
Financial StabilityGHRS's current cash balance is expected to provide financial stability and support operations into 2026.
Regulatory ProgressThe FDA had no additional requests related to the dog toxicology results or to GH's proprietary inhalation device, which were viewed as key hurdles.